breast cancer

Showing 15 posts of 162 posts found.

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

May 23, 2023
Research and Development FDA, Lumicell, Oncology, breast cancer, oncology

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New …


Polyphor’s future in question after co-primary endpoint in breast cancer study missed

June 28, 2021
Sales and Marketing Primary Endpoint, breast cancer

Swiss biopharmaceutical company, Polyphor, has announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin …

Medical cannabis formulation kills breast cancer cells in trial

June 28, 2021
Sales and Marketing breast cancer, medical cannabis, oncology

UK-based pharma company, Apollon Formularies, have announced that their medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) …

Novartis report longest median OS in breast cancer study

June 3, 2021
Novartis, breast cancer, trials

Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …


Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …


Takeda’s breast cancer treatment approved in Scotland

February 9, 2021
Manufacturing and Production Takeda, breast cancer

The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …

Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer

December 9, 2020
Research and Development Kisqali, Novartis, breast cancer

Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …


University of Illinois at Chicago’s new breast cancer drug is safe and can halt disease progression, according to a Phase 1 trial

August 28, 2020
Medical Communications Cancer, Cancers, breast cancer

A new breast cancer drug, called TTC-352, can halt the spread of the disease and is safe according to a …


Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer

July 29, 2020
Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma

The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …


Roche’s Phesgo combo secures US approval for metastatic HER2-positive breast cancer

June 30, 2020
Manufacturing and Production, Sales and Marketing FDA, Phesgo, Roche, US, breast cancer

The FDA has awarded marketing authorisation in the US to Roche’s Phesgo, a combination of subcutaneously injected Herceptin (trastuzumab) with …

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …

FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule

April 23, 2020
Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma

Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …

Prostate Cancer becomes most commonly diagnosed cancer in England

January 28, 2020
Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …

Latest content